FY2026 Earnings Forecast for Savara Issued By HC Wainwright

Savara Inc. (NASDAQ:SVRA – Free Report) – Equities research analysts at HC Wainwright issued their FY2026 earnings estimates for Savara in a report issued on Thursday, November 12th. HC Wainwright analyst M. Caufield anticipates that the company will post earnings of ($0.65) per share for the year. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Savara’s current full-year earnings is ($0.68) per share. HC Wainwright also issued estimates for Savara’s Q4 2026 earnings at ($0.17) EPS, FY2027 earnings at ($0.41) EPS, FY2028 earnings at ($0.08) EPS, FY2029 earnings at $0.13 EPS and FY2030 earnings at $0.32 EPS.

Several other research analysts have also issued reports on the company. Royal Bank Of Canada set a $10.00 price target on Savara in a report on Wednesday, October 7th. Citigroup restated a “market outperform” rating on shares of Savara in a report on Wednesday, October 7th. JPMorgan Chase & Co. began coverage on Savara in a report on Wednesday, October 7th. They set an “overweight” rating and a $12.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Savara in a research report on Thursday, October 15th. Finally, Wall Street Zen cut Savara from a “hold” rating to a “sell” rating in a report on Sunday, October 4th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $10.29.

Check Out Our Latest Stock Analysis on Savara

Savara Price Performance

Shares of Savara stock opened at $4.47 on Monday. The business has a 50-day simple moving average of $4.92 and a 200 day simple moving average of $5.33. Savara has a one year low of $4.13 and a one year high of $7.01. The company has a quick ratio of 10.13, a current ratio of 8.55 and a debt-to-equity ratio of 0.28.

Savara (NASDAQ:SVRA – Get Free Report) last released its quarterly earnings data on Monday, November 9th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.01.

Institutional Trading of Savara

Several institutional investors and hedge funds have recently modified their holdings of SVRA. Sterling Capital Management LLC grew its stake in shares of Savara by 842.8% in the 3rd quarter. Sterling Capital Management LLC now owns 5,063 shares of the company’s stock worth $26,000 after acquiring an additional 4,526 shares in the last quarter. Principal Financial Group Inc. purchased a new stake in shares of Savara in the first quarter valued at about $57,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Savara during the third quarter valued at about $54,000. Sequoia Financial Advisors LLC bought a new position in shares of Savara during the second quarter valued at about $69,000. Finally, E Fund Management Co. Ltd. bought a new position in shares of Savara during the second quarter valued at about $77,000. 87.93% of the stock is owned by hedge funds and other institutional investors.

Savara Company Profile

(Get Free Report)

Savara is a biopharmaceutical company focused on developing treatments for serious and rare respiratory diseases. The company is based in the United States and concentrates its research and development efforts on conditions with limited treatment options. Savara’s lead product candidate is molgramostim, an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). It has been developed as a potential treatment for autoimmune pulmonary alveolar proteinosis, a rare lung disease in which the buildup of material in the air sacs can impair breathing.

Featured Articles

Earnings History and Estimates for Savara (NASDAQ:SVRA)

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.